Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
FULC•Financing and lead asset details
Slate secured $245 million in an oversubscribed private placement set to close alongside the merger, funding operations into 2029.
Slate’s lead asset, SLTE-1009, targets PACAP/VIP for migraine prevention. Phase 1 data are expected mid-2027.
Fulcrum plans a pre-close cash dividend tied to net cash above $20.3 million.
Fulcrum Therapeutics and Slate Medicines to combine
Fulcrum Therapeutics agreed to an all-stock merger with Slate Medicines, creating a migraine-focused company to be renamed Slate Medicines.
Combined shares are expected to trade on Nasdaq under ticker SLTE once the deal closes.
